IRIS Accounts Production v24.3.0.553 07242531 director 31.5.23 30.5.24 30.5.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh072425312023-05-30072425312024-05-30072425312023-05-312024-05-30072425312022-05-31072425312022-06-012023-05-30072425312023-05-3007242531ns15:EnglandWales2023-05-312024-05-3007242531ns14:PoundSterling2023-05-312024-05-3007242531ns10:Director12023-05-312024-05-3007242531ns10:PrivateLimitedCompanyLtd2023-05-312024-05-3007242531ns10:SmallEntities2023-05-312024-05-3007242531ns10:AuditExempt-NoAccountantsReport2023-05-312024-05-3007242531ns10:SmallCompaniesRegimeForDirectorsReport2023-05-312024-05-3007242531ns10:SmallCompaniesRegimeForAccounts2023-05-312024-05-3007242531ns10:FullAccounts2023-05-312024-05-300724253112023-05-312024-05-3007242531ns10:OrdinaryShareClass12023-05-312024-05-3007242531ns5:CurrentFinancialInstruments2024-05-3007242531ns5:CurrentFinancialInstruments2023-05-3007242531ns5:ShareCapital2024-05-3007242531ns5:ShareCapital2023-05-3007242531ns5:RetainedEarningsAccumulatedLosses2024-05-3007242531ns5:RetainedEarningsAccumulatedLosses2023-05-3007242531ns10:RegisteredOffice2023-05-312024-05-3007242531ns5:IntangibleAssetsOtherThanGoodwill2023-05-312024-05-3007242531ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-05-312024-05-3007242531ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-05-3007242531ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-05-3007242531ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-05-3007242531ns5:FurnitureFittings2023-05-3007242531ns5:MotorVehicles2023-05-3007242531ns5:FurnitureFittings2023-05-312024-05-3007242531ns5:MotorVehicles2023-05-312024-05-3007242531ns5:FurnitureFittings2024-05-3007242531ns5:MotorVehicles2024-05-3007242531ns5:FurnitureFittings2023-05-3007242531ns5:MotorVehicles2023-05-3007242531ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-05-3007242531ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-05-3007242531ns10:OrdinaryShareClass12024-05-30
REGISTERED NUMBER: 07242531 (England and Wales)















Unaudited Financial Statements for the Year Ended 30th May 2024

for

Core Health Limited

Core Health Limited (Registered number: 07242531)






Contents of the Financial Statements
for the Year Ended 30th May 2024




Page

Balance Sheet 1

Notes to the Financial Statements 3


Core Health Limited (Registered number: 07242531)

Balance Sheet
30th May 2024

30.5.24 30.5.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 1,645 987
1,645 987

CURRENT ASSETS
Debtors 6 9,745 150
Investments 7 22,703 110,333
Cash at bank 47,479 56,924
79,927 167,407
CREDITORS
Amounts falling due within one year 8 83,949 98,302
NET CURRENT (LIABILITIES)/ASSETS (4,022 ) 69,105
TOTAL ASSETS LESS CURRENT
LIABILITIES

(2,377

)

70,092

PROVISIONS FOR LIABILITIES 341 341
NET (LIABILITIES)/ASSETS (2,718 ) 69,751

CAPITAL AND RESERVES
Called up share capital 9 10 10
Retained earnings (2,728 ) 69,741
SHAREHOLDERS' FUNDS (2,718 ) 69,751

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th May 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Core Health Limited (Registered number: 07242531)

Balance Sheet - continued
30th May 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 24th January 2025 and were signed by:





Mrs B R K Solanki - Director


Core Health Limited (Registered number: 07242531)

Notes to the Financial Statements
for the Year Ended 30th May 2024

1. COMPANY INFORMATION

Core Health Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 07242531

Registered office: The Lexicon
10-12 Mount Street
Manchester
M2 5NT

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from contracts for the provision of professional services is recognised on delivery on the service. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

Core Health Limited (Registered number: 07242531)

Notes to the Financial Statements - continued
for the Year Ended 30th May 2024

2. ACCOUNTING POLICIES - continued

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of nil years.

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs 10 years straight line basis

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment - 3 years straight line basis
Motor vehicles - 5 years straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Core Health Limited (Registered number: 07242531)

Notes to the Financial Statements - continued
for the Year Ended 30th May 2024

2. ACCOUNTING POLICIES - continued

Fixed asset investments
Investments in cryptocurrencies are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in profit or loss. Transaction costs are expensed to profit or loss as incurred.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. INTANGIBLE FIXED ASSETS
Development
costs
£   
COST
At 31st May 2023
and 30th May 2024 115,500
AMORTISATION
At 31st May 2023
and 30th May 2024 115,500
NET BOOK VALUE
At 30th May 2024 -
At 30th May 2023 -

5. TANGIBLE FIXED ASSETS
Fixtures
and Motor
fittings vehicles Totals
£    £    £   
COST
At 31st May 2023 4,565 79,080 83,645
Additions 2,298 - 2,298
At 30th May 2024 6,863 79,080 85,943
DEPRECIATION
At 31st May 2023 3,578 79,080 82,658
Charge for year 1,640 - 1,640
At 30th May 2024 5,218 79,080 84,298
NET BOOK VALUE
At 30th May 2024 1,645 - 1,645
At 30th May 2023 987 - 987

Core Health Limited (Registered number: 07242531)

Notes to the Financial Statements - continued
for the Year Ended 30th May 2024

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.5.24 30.5.23
£    £   
Trade debtors 9,745 -
Other debtors - 150
9,745 150

7. CURRENT ASSET INVESTMENTS
30.5.24 30.5.23
£    £   
Other 22,703 110,333

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.5.24 30.5.23
£    £   
Trade creditors 2 1
Tax 3,436 4,636
Social security and other taxes (668 ) -
VAT 1,850 1,083
Directors' current accounts 76,044 90,802
Accruals and deferred income 3,185 1,780
Accrued expenses 100 -
83,949 98,302

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.5.24 30.5.23
value: £    £   
10 Ordinary 1 10 10

10. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The company operated a loan account with the director, Mrs B Solanki. At the balance sheet date, Core Health Limited owed Mrs B Solanki £76,044 (2023: £90,801) and this amount is included within other creditors.

Dividends of £87,776 (2023: £87,776) were issued in respect of shares held by the director.
The loan is interest free and is repayable on demand.

11. ULTIMATE CONTROLLING PARTY

The controlling party is Mrs B R K Solanki.